Neural and autonomic regulation during brief mindfulness and relaxation interventions in clinical populations: a multimodal MEG study protocol
Perceived organizational climate and turnover intention among young nurses from a humanistic care perspective: the mediating role of work engagement
Cultural adaptation and feasibility of action over inertia in Japan: a multi-site pilot intervention study
Social anxiety but not callous-unemotional traits predicts shame coping in conduct disorder
STAT+: Enliven Therapeutics’ leukemia drug shows promise in new study
A targeted drug from Enliven Therapeutics induced molecular responses in nearly half of patients with advanced leukemia, including higher response rates in patients treated at an earlier stage of their disease.
The updated early-stage study results reported Thursday for the Enliven drug, ELVN-001, compare favorably to a current blockbuster medicine sold by Novartis and an upstart experimental drug recently bought by Merck.
At 24 weeks, an 80 mg, once-daily dose of ELVN-001 achieved a major molecular response in 48% of patients with chronic myeloid leukemia, or CML, a slow-growing cancer that starts in myeloid cells.
Evaluating Postpartum Hemorrhage Transfusion Risk With a Machine Learning Model for Informed Consent: Retrospective Cohort Study
HHS responds coolly to paper on alcohol risk
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.
Good morning. Today we’ve got an item from STAT’s new AAAS media fellow Lauren Chan. She’ll be reporting with us this summer. Scroll down to read her report on a sugary soda study.

